Phase3 Study to Evaluate the Efficacy and Safety of AlbuminInterferon in Combination With Ribavirin Compared With Peginterferon in Combination With Ribavirin in Interferon Alfa Naive Subjects With CHC Genotype 2/3.
Phase3 Study to Evaluate the Efficacy and Safety of AlbuminInterferon in Combination With Ribavirin Compared With Peginterferon in Combination With Ribavirin in Interferon Alfa Naive Subjects With CHC Genotype 2/3.
This is a phase 3, randomized, multi-center study to evaluate the efficacy and safety of albumin interferon alfa-2b (alb-IFN)in combination with ribavirin compared with peginterferon alfa-2a (PEGASYS or PEG-IFNa2a) in combination with ribavirin in subjects with chronic hepatitis C, genotype 2/3 who are IFNa treatment naive.
Key Inclusion Criteria:
Key Exclusion Criteria:
Lancaster, Pennsylvania 17604-3200, United States
Capital Federal, Buenos Aires C1093AAS, Argentina
Capital Federal, Buenos Aires C1121ABE, Argentina
Capital Federal, Buenos Aires C1181ACH, Argentina
Greenslopes, Queensland 4120, Australia
Heidelburg, Victoria 3081, Australia
Salvador, Estado de Bahia 40110-170, Brazil
Ribeirão Preto, São Paulo 14049-900, Brazil
Monterrey N.L., CP 64460, Mexico
Bundang, 463-712, South Korea
Seonnam City, 463-802, South Korea
Badalona - Barcelona, 8916, Spain